Treatment of pulmonary arterial hypertension (PAH);Therapie der pulmonal arteriellen Hypertonie (PAH)

Deutsche Medizinische Wochenschrift

Volumn 135, Issue SUPPL. 3, 2010, Pages

  Ghofrani, H Ardeschir ^a   Distler, O ^b   Gerhardt, F ^c   Gorenflo, M ^d   Grunig E ^e   Haefeli, W E ^f   Held, M ^g   Hoeper, M M ^h   Kahler C M ⁱ   Kaemmerer, H ^j   Klose, H ^k   Kollner V ^l   Kopp, B ^m   Mebus, S ^j   Meyer, A ⁿ   Miera, O ^o   Pittrow, D ^p   Riemekasten, G ^q   Rosenkranz, S ^c   Schranz, D ^r   Voswinckel, R ^a   Olschewski, H ^s   more..

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Department of Pediatric Cardiology ^*  (Belgium)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g Missionsärztliches Institut Würzburg   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l MediClin Bliestal Kliniken   (Germany)

^m Pulmonale Hypertonie EV (Phev)   (Germany)

ⁿ KLINIKEN MARIA HILF GMBH   (Germany)

^o DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^p DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^q CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^r JUSTUS LIEBIG UNIVERSITY   (Germany)

^s UNIVERSITY HOSPITAL GRAZ   (Austria)

more..

Author keywords

endothelin receptor antagonists; phosphodiesterase type 5 inhibitors; prostanoids; pulmonary arterial hypertension (PAH); treatment

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; ILOPROST; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN; VASODILATOR AGENT;

CONFERENCE PAPER; HUMAN; PATIENT COMPLIANCE; PROGNOSIS; PULMONARY HYPERTENSION; TREATMENT OUTCOME; TREATMENT RESPONSE; ALGORITHM; CONSENSUS DEVELOPMENT; COOPERATION; DRUG COMBINATION; EVIDENCE BASED MEDICINE; FEMALE; GENETICS; GERMANY; HYPERTENSION, PULMONARY; INTERDISCIPLINARY COMMUNICATION; KINESIOTHERAPY; MULTIMODALITY CANCER THERAPY; OXYGEN THERAPY; PATIENT CARE; PRACTICE GUIDELINE; PREGNANCY; PSYCHOLOGY;

ALGORITHMS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; CALCIUM CHANNEL BLOCKERS; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; DIGOXIN; DRUG THERAPY, COMBINATION; ENDOTHELIN RECEPTOR ANTAGONISTS; EVIDENCE-BASED MEDICINE; EXERCISE THERAPY; FEMALE; GERMANY; HUMANS; HYPERTENSION, PULMONARY; INTERDISCIPLINARY COMMUNICATION; OXYGEN INHALATION THERAPY; PATIENT CARE TEAM; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; PREGNANCY; PROSTAGLANDINS; VASODILATOR AGENTS;

EID: 77957375146     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1263316     Document Type: Conference Paper

References (58)

1. Barst R J., Ivy D, Dingemanse J, Widlitz A et al. Pharmacokinetics, safety and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003 73 372-382 (Pubitemid 36403597)
2. Barst R J., Langleben D, Badesch D et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006 47 2049-2056
3. Barst R J., Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004 169 441-447 (Pubitemid 38187114)
4. Barst R J., Rubin L J., Long W A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996 334 296-302
5. Beghetti M, Haworth S G., Bonnet D et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009 68 948-955
6. Bull T M., Fagan K A., Badesch D B. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 2005 31 451-464, vi (Pubitemid 41111548)
7. Carlsen J, Kjeldsen K, Gerstorft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002 16 1568-1569 (Pubitemid 34804229)
8. Channick R N., Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001 358 1119-1123 (Pubitemid 32971843)
9. Chau E M., Fan K Y., Chow W H. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007 120 301-305 (Pubitemid 47069563)
10. Degano B, Yaici A, Le Pavec J et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009 33 92-98
11. De Man F S., Handoko M L., Groepenhoff H et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009 34 669-675
12. Dimopoulos K, Inuzuka R, Goletto S et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010 121 20-25
13. Dupuis J, Hoeper M M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008 31 407-414
14. Evgenov O V., Pacher P, Schmidt P M. et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006 5 755-768 (Pubitemid 44323702)
15. Fernandes S M., Newburger J W., Lang P et al. Usefullness of epoprostenol therapy in the severly ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 2003 91 632-635 (Pubitemid 36263277)
16. Galie N, Beghetti M, Gatzoulis M A. et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006 114 48-54 (Pubitemid 44305274)
17. Galie N, Brundage B H., Ghofrani H A. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009 119 2894-2903 (Pubitemid 41040298)
18. Galie N, Ghofrani H A., Torbicki A et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2005 353 2148-2157 (Pubitemid 41653106)
19. Gali N, Hoeper M M., Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009 30 2493-2537
20. Gali N, Hoeper M M., Humber M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009 34 1219-1263
21. Galie N, Manes A, Negro L et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009 30 394-403
22. Galie N, Olschewski H, Oudiz R J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008 117 3010-3019
23. Galie N, Rubin L, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008 371 2093-2100 (Pubitemid 351902178)
24. Ghofrani H A., Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur Respir Rev 2009 18 35-41
25. Ghofrani H A., Hoeper M M., Halank M et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010a (in press)
26. Ghofrani H A., Morrell N W., Hoeper M M. et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010b
27. Grannas G, Neipp M, Hoeper M M. et al. Indications for and Outcomes After Combined Lung and Liver Transplantation: A Single-Center Experience on 13 Consecutive Cases. Transplantation 2008 85 524-531
28. Haworth S G., Hislop A A. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 20012006. Heart 2009 95 312-317
29. Hoeper M M., Gall H, Seyfarth H J. et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 2009 34 132-137
30. Hoeper M M., Ghofrani H A., Gorenflo M et al. Diagnostik und Therapie der pulmonalen Hypertonie: Europäische Leitlinien 2009. Pneumologie 2010 64 401-414
31. Hoeper M M., Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005 26 858-863 (Pubitemid 41632043)
32. Hoeper M M., Seyfarth H J., Hoeffken G et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007 30 1096-1102 (Pubitemid 351194755)
33. Krasuski R A., Hart S A., Smith B et al. Association of anemia and long-term survival in patients with pulmonary hypertension. Int J Cardiol 2010 (in press)
34. Ladwig K H., Baumert J, Marten M et al. Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: results from the prospective living with an implanted cardioverter-defibrillator study. Arch Gen Psychiatry 2008 65 1324-1330
35. McLaughlin V V., Benza R L., Rubin R J. et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2010 55 1915-1922
36. McLaughlin V V., Oudiz R J., Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006 174 1257-1263 (Pubitemid 44924827)
37. Mereles D, Ehlken N, Kreuscher S et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006 114 1482-1489 (Pubitemid 44527003)
38. Moledina S, Hislop A A., Foster H, Schulze-Neick I, Haworth S G. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 2010 (Epub ahead of print)
39. Mukerjee D, St G eorge D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003 62 1088-1093 (Pubitemid 37323574)
40. Mukhopadhyay S, Sharma M, Ramakrishnan S et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 2006 114 1807-1810 (Pubitemid 44673355)
41. Olschewski H, Gomberg-Maitland M. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008 31 801-901 (Pubitemid 351945661)
42. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002 347 322-329 (Pubitemid 34815354)
43. Oudiz R J., Galie N, Olschewski H et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009 54 1971-1981
44. Perros F, Montani D, Dorfmüller P et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008 178 81-88 (Pubitemid 351919196)
45. Reichenberger F, Voswinckel R, Steveling E et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006 28 563-567 (Pubitemid 44794671)
46. Rosenzweig E B., Ivy D D., Wildlitz A et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005 46 697-704 (Pubitemid 41132700)
47. Rubin L J., Badesch D B., Barst R J. et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002 346 896-903 (Pubitemid 34984638)
48. Schermuly R T., Dony E, Ghofrani H A. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005 115 2811-2821 (Pubitemid 41434408)
49. Schumacher Y O., Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001 15 1747-1748
50. Simonneau G, Barst R J., Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002 165 800-804 (Pubitemid 34229650)
51. Simonneau G, Rubin L J., Galie N et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008 149 521-530
52. Sitbon O, Gressin V, Speich R et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004 170 1212-1217 (Pubitemid 39577380)
53. Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005 111 3105-3111 (Pubitemid 40847788)
54. Sitbon O, Lascoux-Combe C, Delfraissy J F. et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008 177 108-113
55. Thamm M, Voswinckel R, Gall H et al. Air travel is safe and well tolerated in clinically stable patients with stable pulmonary hypertension. ATS PH patients. Am J Respir Crit Care Med 2009 179 A3371 (Abstract)
56. Tongers J, Schwerdtfeger B, Klein G et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007 153 127-132 (Pubitemid 44889238)
57. Whooley M A., Simon G E. Managing depression in medical outpatients. N Engl J Med 2000 343 1942-1950
58. Wilkins M R., Wharton J, Grimminger F, Ghofrani H A. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008 32 198-209